Compare Amgen, Inc. (AMGN) vs Xylem, Inc. (XYL) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amgen, Inc. vs Xylem, Inc. — how do they compare? Amgen, Inc. trades at $363.55 (market cap $196.12B), while Xylem, Inc. trades at $120.88 (market cap $28.81B). The key difference: Amgen, Inc. is far larger — about 6.8× Xylem, Inc.'s market cap, and Amgen, Inc. pays the higher dividend (2.77%). Which is the better fit depends on your goals.
| AMGN | XYL | |
|---|---|---|
Market Cap | $196.12B | $28.81B |
Sector | Health | Industrials |
52-Week High | $388.16 | $152.95 |
52-Week Low | $271.18 | $106.34 |
Enterprise Value | $241.41B | $30.07B |
Dividend Yield | 2.77% | 1.42% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMGN trades at $363.39, down slightly by 0.06% today, with a bullish technical signal from moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $5.15 versus $4.77 expected. Revenue grew to $36.75B in 2025, with a net income margin of 20.96%. Recent news includes a favorable court ruling blocking a price cap on Enbrel in Colorado, but regulatory challenges persist for Tavneos in Europe.
The outlook remains positive due to consistent earnings beats and a diversified product portfolio, though risks include regulatory setbacks and competitive pressures. Analyst consensus is bullish with a 57.9% buy rating and a price target of $357.38, slightly below the current price, indicating potential for stability with upside from pipeline developments.
XYL trades at $121.22, up 1.96% with a bullish technical outlook. The stock shows consistent earnings beats, with Q1 2026 EPS of $1.12 exceeding expectations. Revenue grew to $9.04B in 2025, and net income margin improved to 10.79%. Recent news highlights strategic partnerships and leadership appointments, reinforcing growth in water technology solutions. The company maintains a strong balance sheet with total assets of $16.49B and shareholder equity of $10.64B as of 2024.
XYL presents a favorable investment case with analyst consensus price target of $153.14, implying 26% upside. Strengths include steady revenue growth, expanding margins, and positive cash flow trends. Risks involve market volatility and execution challenges in scaling new partnerships. Institutional sentiment is mixed but leans bullish, supported by a 47.5% buy rating from analysts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About Xylem, Inc.
Xylem is a global leader in water technology and offers a wide range of solutions, including the transport, treatment, testing, and efficient use of water for customers in the utility, industrial, commercial, and residential sectors. Xylem was spun off from ITT in 2011. Based in Rye Brook, New York, Xylem has a presence in over 150 countries and employs 16,200. The company generated $6.2 billion in revenue and $611 million in adjusted operating income in 2021.
Read more on XYL →
